FINCH THERAPEUTICS GROUP, INC. : Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 2.05 Costs associated with eviction or disposal activities.

upon January 24, 2023, Finch Therapeutics Group (the “Company”) announced its decision to discontinue a Phase 3 clinical trial of CP101 in recurrent C. difficile infections and focus on realizing the value of its intellectual property and other assets . In connection with these decisions: January 23, 2023, the Company’s Board of Directors has approved certain cost-cutting measures, including the reduction of the Company’s workforce (“restructuring”) by 77 full-time employees, or approximately 95% of the Company’s current employee base. .Our company has started restructuring January 24, 2023the majority of affected positions are February 2023 and a small fraction of the positions held May 2023.

As a result of the restructuring, the Company $4.1 million Expenses arising from cash outlays consisting of single severance payments, placement services and related costs. The Company expects to book the majority of these charges in the first half of 2023. The restructuring is expected to be substantially completed by the end of the second quarter of 2023. Estimates and Timing of Costs We Expect to Incur are Based on Various Assumptions and Actual Results May Vary. We may also incur other currently unanticipated costs or cash outlays related to restructuring.

————————————————– ——————————

Section 7.01 Regulation FD Disclosure.

upon January 24, 2023, the Company issued a press release regarding the restructuring. A copy of the press release is provided as Exhibit 99.1 to this current report on Form 8-K.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is provided and is not to be considered “filed” for the purposes of the Exchange Act of 1934, as amended (the “Exchange Act”). shall not be considered and shall not be deemed incorporated. By reference in filings under the Securities Act of 1933, as amended, or the Securities Exchange Act, except where expressly stated by specific reference in such filings.

Cautionary Note Regarding Forward-Looking Statements

This current report on Form 8-K (this “current report”) contains “forward-looking statements”. Words such as “will,” “expect,” “believe,” “expect,” “intend,” “plan,” “could,” “project,” “would,” “future,” or similar The representation of is intended to identify forward. -A look statement. These forward-looking statements include our focus on realizing the value of our intellectual property and other assets, our estimate of costs to be incurred in connection with the restructuring, and our anticipated including, but not limited to, timing statements. Timing of restructuring completion and related costs. Such statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, those related to: impediment to our ability to restructure or identify opportunities to realize the value of our currently contemplated intellectual property and other assets; Risk that restructuring costs and expenses may be higher than expected. the risk that our restructuring efforts may adversely affect our ability to retain skilled and motivated personnel and may be distracting to our employees and management; the risk that our restructuring efforts may adversely affect our business operations and reputation; The risk that the Company’s restructuring efforts may not produce the intended benefits to the extent or promptly expected. our ability to comply with legal and regulatory requirements; Also, our ability to maintain patent and other intellectual property protections and the possibility that our intellectual property rights may be infringed, invalid, unenforceable, or threatened by third parties.For these and other risks, we Securities and Exchange Commission (“SEC”), which includes a section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended. December 31, 2021 submitted to SEC upon March 31, 2022supplemented by the company’s quarterly report on Form 10-Q filed at SEC upon May 16, 2022, August 11, 2022 When November 10, 2022and discussion in our other filings of potential risks, uncertainties and other material factors SECAll forward-looking statements contained in this current report speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to update such statements to reflect events or circumstances occurring after the date such statements were made.

————————————————– ——————————

Item 9.01 Financial Statements and Materials.

(d) Exhibits

Exhibit                                   Description
Number
  99.1      Press Release, dated January 24, 2023  .
  104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

————————————————– ——————————

© Edgar Online, Source glance